Effects of PRK 124 Lotion in Acne Rosacea
This study has been completed.
Sponsor:
University of California, Irvine
Collaborator:
SenetekPLC
Information provided by:
University of California, Irvine
ClinicalTrials.gov Identifier:
NCT00580723
First received: December 21, 2007
Last updated: March 12, 2009
Last verified: March 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this open-label study is to determine the tolerance and efficacy of twice-daily application of PRK 124 (Pyratine-6)(0.125%) moisturizing lotion for improving the signs and symptoms of mild to moderate facial rosacea.
| Condition | Intervention | Phase |
|---|---|---|
|
Acne Rosacea |
Other: PRK 124 |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Effects of PRK 124 (0.125%) Lotion in Acne Rosacea |
Resource links provided by NLM:
Further study details as provided by University of California, Irvine:
Primary Outcome Measures:
- Inflammatory lesion count, erythema and telangiectasia [ Time Frame: Baseline, Weeks 1, 4, 8, 12, 24, 36, 48 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Skin Tolerance [ Time Frame: Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 ] [ Designated as safety issue: Yes ]
- Skin photodamage [ Time Frame: Baseline, Weeks 1, 4, 8, 12, 24, 36, 48 ] [ Designated as safety issue: No ]
- Transepidermal water loss (TEWL) [ Time Frame: Baseline, Weeks 1, 4, 8, 12, 24, 36, 48 ] [ Designated as safety issue: No ]
- Cosmetic acceptability [ Time Frame: Baseline, Weeks 1, 4, 8, 12, 24, 36, 48 ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 24 |
| Study Start Date: | April 2007 |
| Study Completion Date: | February 2009 |
| Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: A
Topical PRK 124 (Pyratine-6)(0.125%)
|
Other: PRK 124
Topical PRK 124 (0.125%) moisturizing lotion applied twice daily to the face for 48 weeks
Other Names:
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 21 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- be at least 21 years old
- be in reasonably good health as defined by the study doctor
- have routine laboratory tests to evaluate your blood cell count, and kidney and liver function
- for females of child-bearing age, not be pregnant or nursing and have a negative urine pregnancy test (except if surgically sterile or at least 1 year menopausal)
- for females, agree to use medically acceptable forms of birth control throughout the entire study (medically acceptable forms of birth control include oral contraceptive ["the pill"], implants such as Norplant®, injectable progesterone [Depo-provera®], diaphragm and spermicide or condoms and spermicide)
- must have mild to moderate acne rosacea
- be willing to refrain from using non-approved lotions, moisturizer, cleansers or lotions on affected facial areas during the treatment period
- be capable of understanding and giving written, voluntary informed consent before study screening
- be willing to consent to facial photographs at baseline and each follow-up visit to monitor treatment with the test product.
Exclusion Criteria:
- have a history or evidence of any chronic or reoccurring skin disease or disorder (e.g., psoriasis, eczema, etc.) affecting the face
- have known or suspected hypersensitivity to study treatment or any of its ingredients
- have used systemic retinoids within 6 months prior to study entry (e.g., acitretin, isotretinoin)
- have received treatment with systemic corticosteroids (e.g. prednisone) or antibiotics within 1 month
- have used topical treatment to the face with retinoids (e.g. tretinoin, adapalene), or antibiotics or corticosteroids, within 2 weeks prior to study entry
- are unwilling to use a sunscreen with an SPF of 30 during the study
- have participated in any clinical trial involving an investigational drug or cosmetic product or procedure within the past 30 days
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00580723
Locations
| United States, California | |
| UC Irvine Dermatology Clinical Research Center | |
| Irvine, California, United States, 92697 | |
Sponsors and Collaborators
University of California, Irvine
SenetekPLC
Investigators
| Principal Investigator: | Gerald D Weinstein, MD | University of California, Irvine |
More Information
Additional Information:
Publications:
| Responsible Party: | Gerald D. Weinstein, MD, University of California, Irvine |
| ClinicalTrials.gov Identifier: | NCT00580723 History of Changes |
| Other Study ID Numbers: | 2006-5307, Contract SPLC-41239 |
| Study First Received: | December 21, 2007 |
| Last Updated: | March 12, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of California, Irvine:
|
acne rosacea acne rosacea papulopustular rosacea |
erythema telangiectasia flushing |
Additional relevant MeSH terms:
|
Acne Vulgaris Rosacea Acneiform Eruptions |
Skin Diseases Facial Dermatoses Sebaceous Gland Diseases |
ClinicalTrials.gov processed this record on May 22, 2013